
Leading Health Care Experts Highlight Rapid Pace of Innovation in Medicine, MedTech and AI at NHC Symposium
WASHINGTON--(BUSINESS WIRE)--Leading health care and patient advocacy experts outlined the rapid pace of medical innovation at the National Health Council (NHC) Science of Patient Engagement Symposium, and discussed the many ways technology is transforming patient diagnosis, treatment and quality of life. The conference, entitled, Elevating Innovation: Medicine, MedTech, and AI, held May 7-8 at the National Press Club, brings together more than 150 policymakers, researchers, patients and patient advocates, and health care providers.
Keeping patient needs at the center of health care amidst technological progress is essential
The Symposium, held annually, explores standards and best practices that ensure every patient has legitimate input in their own medical care and that research is co-created with patients and results are applied equally to all individuals. Each conference panel session includes a moderator or panelist from the patient community.
'This Symposium brings together the most influential, experienced and passionate leaders to ensure the needs of patients are being met as they navigate our complex health care system,' said Randall L. Rutta, NHC CEO. 'As medical technology delivers astonishing advancements, we must ensure the needs of patients remain at the forefront of care. That is the critically important focus of this Symposium.'
The Symposium examined the science of patient engagement from the perspectives of both patients and medical experts. Keynote speakers included:
Nicholas Webb, number one best-selling author and Chief Executive Officer of LeaderLogic, LLC, The Science of Patient Engagement in an era of Chaotic Change.
Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, Insilico Medicine, Putting Patients First in Drug Discovery, a Few AI-driven Case Studies.
Brian Anderson, MD, Chief Executive Officer – Coalition for Health AI, Human Flourishing in an Age of Health AI.
'This Symposium not only convenes some of the most influential voices in health care, it serves as a laboratory for new ideas and new ways of doing things that ensures patients not only get the best care available, but that they also have a legitimate voice and proper role in their own health care decisions,' said Dr. Devin Jopp, CEO of the Association for Professionals in Infection Control and Epidemiology, and Chair of the NHC's Research and Programs Committee.
Additional conference highlights and speakers included:
In the opening session, Karl Cooper, Esq., Executive Director, American Association on Health and Disability moderated a session, Teamwork Makes the Dream Work: Bridging the Gap Between MedTech and Patient Needs, discussed the novel ways tech companies and patients are collaborating in the development of medical devices and wearables.
Dr. Raj Ratwani, Vice President of Scientific Affairs, MedStar Health Research Institute and Professor, Georgetown University School of Medicine, Integrating Precision Medicine and Health Systems into AI Innovation, led a conversation about how AI is streamlining operations and supporting precision medicine initiatives – and ethical principles – to create smarter, more responsive health care systems that benefit patients and their family caregivers.
A pre-conference workshop session, Empathy-First Innovation: How to Embed Patient Advocacy in the Design Process, introduced actionable frameworks for empathy-first innovation and demonstrated how to make patient advocates an integral part of a company's innovation journey.
The Science of Patient Engagement Symposium is an annual event where research leaders convene to share their experiences, accomplishments, best practices, and resulting translational impacts on the science of patient engagement.
About NHC
Created by and for patient organizations more than 100 years ago, the National Health Council (NHC) brings diverse organizations together to forge consensus and drive patient-centered health policy. We promote increased access to affordable, high-value, sustainable health care. Made up of more than 180 national health-related organizations and businesses, the NHC's core membership includes the nation's leading patient organizations. Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses representing biopharmaceutical, device, diagnostic, generic drug, and payer organizations. Learn more at: https://www.nationalhealthcouncil.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. WALTHAM, Mass. & GENEVA, Switzerland, June 10, 2025--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections and the World Health Organization (WHO) identifying antimicrobial resistance (AMR) as one of the ten most critical global threats to public health, the bacterium Neisseria gonorrhoeae has progressively developed resistance to many classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. "Today's acceptance of the zoliflodacin NDA marks significant progress toward delivering health care providers with a potential new oral treatment option for uncomplicated gonorrhea, including infections caused by drug-resistant strains," said David Altarac, M.D., Chief Medical Officer, Innoviva Specialty Therapeutics. "We look forward to working closely with the FDA during its review and, if approved, we are committed to expediting the availability of zoliflodacin to patients in the U.S." Recent reports (The Lancet Infectious Diseases) of emergent ceftriaxone-resistant infections have heightened the urgency for new antibiotics. Effective treatment options are essential to reducing the burden of disease for individuals and preventing the spread of highly drug-resistant gonorrhea globally. If left untreated, gonorrhea can also cause infertility in women, life-threatening ectopic pregnancies, and pelvic inflammatory disease.2 The FDA's acceptance of the zoliflodacin NDA is based on the totality of data collected from several clinical trials as part of an innovative public-private partnership with GARDP. These trials include a pivotal Phase 3 clinical trial which demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection of a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of ceftriaxone followed by 1 week of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. "This important milestone demonstrates the crucial role that public-private partnerships can play in tackling the escalating global antimicrobial resistance crisis," said Dr. Manica Balasegaram, Executive Director, Global Antibiotic Research Development Partnership (GARDP). "If zoliflodacin is approved, this collaboration paves the way for millions of people across the world to get access to a potentially powerful new drug to treat multidrug-resistant gonorrhea." Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In vitro studies have demonstrated its activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. This investigational antibacterial is administered in a single, oral dose, simplifying treatment by providing a convenient option for patients unable to receive an intramuscular injection. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Innoviva Specialty Therapeutics, Inc., anticipates that the NDA review will proceed according to the standard process for drugs with this designation. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to View source version on Contacts Media Contacts:Innoviva Specialty TherapeuticsDavid +1.908.421.5971GARDPDuncan Graham-Rowedgrahamrowe@ +44 7966 413623 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Fully insured medical claims analysis shows significant cost savings and 2.4x ROI for Hinge Health populations
Methodology validated by leading global benefits consultant SAN FRANCISCO, June 10, 2025--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced results from a medical claims analysis revealing an average $2,343 savings per member per year on care for chronic musculoskeletal (MSK) conditions and a 2.4x return on investment (ROI) for fully insured health plan members using its digital MSK platform. The methodology of the medical claims analysis of 4,788 health plan members was validated by Gallagher, a leading global insurance brokerage, risk management, and consulting firm. MSK costs remain one of the top drivers of health costs, placing increasing pressure on benefits leaders to ensure programs deliver value and cost-efficiency. The medical claims analysis examined the impact of Hinge Health on medical care costs and utilization among participants enrolled in fully insured health plans. The study found meaningful cost savings from reduced utilization across a spectrum of healthcare services, including injections and physical or occupational therapy, with the majority of claims reductions (44%) coming from avoided surgeries. "Employers today face tremendous pressure to contain costs without sacrificing the quality of employee benefits," said Jim Pursley, President, Hinge Health. "This analysis proves that health plans can deliver better health outcomes and an outstanding member experience with Hinge Health, while driving down healthcare spend." The analysis leveraged a claims database that represented more than 100 million commercially insured lives from January 1, 2017 to September 30, 2023. To estimate savings, the study compared medical cost and utilization between Hinge Health participants and a matched control group between a baseline year and the 12 months after Hinge Health members started care. This new analysis builds upon previous cost analysis studies that demonstrate the cost-savings that Hinge Health provides. Hinge Health's digital MSK platform has consistently shown a financial benefit of more than 2x ROI across industries and participant demographics through multiple third-party validations, including a multi-employer study and Medicare population evaluation. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California. View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data